Investigational drug · Phase 3
Saroglitazar Magnesium
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis, Fibrosis.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
3 still active
All registered trials
18
Any phase or sponsor naming "Saroglitazar Magnesium"
First trial start
2021
Aug 18, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Saroglitazar Magnesium", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Biliary Cholangitis
- Nonalcoholic Steatohepatitis
- Fibrosis
Approved drugs for the same conditions: MASH (fatty liver disease) · Primary biliary cholangitis · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Saroglitazar Magnesium" as an intervention, largest first.
- Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical OutcomesPivotal-lookingRecruiting
Zydus Therapeutics Inc.Industry
NCT07216235 · 386 participants (planned) · Start Mar 24, 2026 · Primary completion Nov 2032
Drug: Saroglitazar magnesium 1 mg; Placebo · For: Primary Biliary Cholangitis
Sites: Marietta, Georgia; Indianapolis, Indiana; Houston, Texas
- Saroglitazar Magnesium for Treatment of Primary Biliary CholangitisPivotal-lookingCompleted
Zydus Therapeutics Inc.Industry
NCT05133336 · 196 participants · Start Apr 1, 2022 · Primary completion Apr 30, 2025
Drug: Saroglitazar Magnesium 1 mg; Saroglitazar Magnesium 2 mg and 1 more · For: Primary Biliary Cholangitis
Sites: Birmingham, Alabama; Tucson, Arizona; Los Angeles, California · 57 sites in all
- Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With FibrosisPivotal-lookingCompleted
Zydus Therapeutics Inc.Industry
NCT05011305 · 189 participants · Start Aug 18, 2021 · Primary completion Sep 12, 2025
Drug: Saroglitazar Magnesium 2 mg; Saroglitazar Magnesium 4 mg and 1 more · For: Nonalcoholic Steatohepatitis; Fibrosis
Sites: Birmingham, Alabama; Homewood, Alabama; Phoenix, Arizona · 129 sites in all
- Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dLPivotal-lookingSuspended
Zydus Therapeutics Inc.Industry
NCT03097107 · 124 participants (planned) · Start Apr 6, 2017 · Primary completion Dec 2023
Drug: Saroglitazar Magnesium 1 mg; Saroglitazar Magnesium 2 mg and 2 more · For: Dyslipidemias
Sites: Huntsville, Alabama; Encinitas, California; San Diego, California · 33 sites in all
- Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic SteatohepatitisPivotal-lookingCompleted
Zydus Therapeutics Inc.Industry
NCT03061721 · 106 participants · Start Apr 6, 2017 · Primary completion Aug 22, 2019
Drug: Saroglitazar magnesium 1 mg; Saroglitazar magnesium 2 mg and 2 more · For: Non-Alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis
Sites: Chula Vista, California; Los Angeles, California; Montclair, California · 18 sites in all
- Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary CholangitisPivotal-lookingActive, not recruiting
Zydus Therapeutics Inc.Industry
NCT06427395 · 102 participants · Start Jul 16, 2024 · Primary completion Apr 18, 2027
Drug: Saroglitazar Magnesium 1 mg · For: Primary Biliary Cholangitis
Sites: Los Angeles, California; Pasadena, California; Sacramento, California · 28 sites in all
Zydus Therapeutics Inc.Industry
NCT04469920 · 98 participants · Start Jul 16, 2020 · Primary completion Mar 21, 2022
Drug: Saroglitazar Magnesium 2 mg; Saroglitazar Magnesium 4 mg · For: Hepatic Impairment
Sites: Indianapolis, Indiana; San Antonio, Texas
- Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA TherapyPivotal-lookingRecruiting
Zydus Therapeutics Inc.Industry
NCT07424677 · 90 participants (planned) · Start Aug 11, 2026 · Primary completion Jul 2028
Drug: Saroglitazar Magnesium 1 mg; Placebo · For: Primary Biliary Cholangitis
Sites: Lakewood Rch, Florida
Zydus Therapeutics Inc.Industry
NCT03617263 · 60 participants · Start Feb 12, 2019 · Primary completion Oct 28, 2024
Drug: Saroglitazar Magnesium 4 mg Tablet; Placebo · For: Non-alcoholic Fatty Liver Disease in Women With PCOS
Sites: Chandler, Arizona; Panorama City, California; San Francisco, California · 19 sites in all
- A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy VolunteersCompleted
Zydus Therapeutics Inc.Industry
NCT04045769 · 52 participants · Start Aug 19, 2019 · Primary completion Nov 27, 2019
Drug: Saroglitazar magnesium 4mg; Placebos and 2 more · For: Healthy
Sites: Ahmedabad, India
Newest research
PubMed records naming it or its code names, newest first.
- A phase 2b/3 trial of saroglitazar in primary biliary cholangitis.
Vuppalanchi R, Villamil A, Yilmaz Y, et al. · Hepatology 2026
- Saroglitazar 4ߙMg in Metabolic Dysfunction-Associated Steatotic Liver Disease: 24-Week Results From Phase 4 Study.
Sanyal A, Doshi S, Behl N, et al. · Liver Int 2026
- Effectiveness of Saroglitazar in MASLD Patients: A Prospective, Real-World Assessment of Liver and Metabolic Health.
Gupta M, Lachhwani H, Chandra KP, et al. · Endocrinol Diabetes Metab 2026
- Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment.
Vuppalanchi R, Cruz MM, Momin T, et al. · Clin Pharmacol Ther 2025
- Pharmacokinetics and Safety Evaluation of Single-Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment.
Lawitz E, Parmar D, Momin T, et al. · Clin Pharmacol Drug Dev 2023
- Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients.
Siddiqui MS, Parmar D, Shaikh F, et al. · Liver Transpl 2023
Also in development for Primary Biliary Cholangitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.